Exelixis presented subgroup analysis from the phase 3 CABINET trial. Cabometyx reduced disease progression or death risk by 74% in non-functional advanced neuroendocrine tumors.
The trial enrolled 298 patients. Median progression-free survival was 9.4 months for non-functional and 12.7 months for functional tumors.
Common side effects included hypertension and diarrhea. Cabometyx is approved in the US and EU.
